The CDK12–BRCA1 signaling axis mediates dinaciclib‐associated radiosensitivity through p53‐mediated cellular senescence

Pan‐cyclin‐dependent‐kinase (CDK) inhibitors are a new class of targeted therapies that can act on multiple CDKs, with dinaciclib being one of the most promising compounds. Although used as a monotherapy, an interesting approach could be to combine it with radiotherapy. Here, we show that dinaciclib...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Natalia García Flores, Diego M. Fernández‐Aroca, Cristina Garnés‐García, Andrés Domínguez‐Calvo, Jaime Jiménez‐Suárez, Sebastià Sabater, Pablo Fernández‐Aroca, Ignacio Andrés, Francisco J. Cimas, Guillermo deCárcer, Borja Belandia, Ignacio Palmero, Pablo Huertas, María José Ruiz‐Hidalgo, Ricardo Sánchez‐Prieto
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2025-04-01
Sarja:	Molecular Oncology
Aiheet:	BRCA1 CDK12 dinaciclib radiosensitivity senescence
Linkit:	https://doi.org/10.1002/1878-0261.13773
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!